Biomunex CSO defines lead compounds, early R&D plans
During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different from other cancer therapies in development in this area. Zhukovsky outlines the company's early development design and the timeline for its lead compounds, which are yet to enter the clinic, in solid and hematological cancers.
Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Eugene Zhukovsky – CSO, Biomunex